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n Abstract: There has been an increasing use of bilateral mastectomy (BM) for breast cancer. We sought to examine
our trends among breast conservation (BCT) candidates and women recommended for unilateral mastectomy (UM). Our
prospective breast cancer database was queried for women with a first-time, unilateral breast cancer. Patient and histologic
factors and surgical treatment, including reconstruction, were evaluated. A detailed chart review was performed among
patients from two representative time periods as to the reasons the patient underwent mastectomy. We identified 3,892
women between 2000 and 2012 of whom 60% underwent BCT, 1092 (28%) had UM and 12% underwent BM. BM rose
from 4% in 2000 to a high of 19% in 2011, increasing around 2002 for women <40. BCT was less likely with decreasing
age (p < 0.0001), lobular histology (p < 0.0001), higher stage (p < 0.0001) and decreasing BMI (p < 0.0001). Among mas-
tectomy patients, contralateral mastectomy was associated with decreasing age (p < 0.0001), Caucasian race (p < 0.0001),
and lower stage (p = 0.005). Over time, indications for mastectomy decreased while patients deemed BCT-eligible opting
for UM or BM increased dramatically. Increases in the use of BM are in large part among women who were otherwise
BCT-eligible. Factors associated with BM use are different for BCT-eligible patients and those recommended for UM. A bet-
ter understanding of the factors driving individual patient choices is needed. n
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Over the same period that we have seen a shifttoward less aggressive axillary surgery in breast
cancer, we have seen a parallel shift toward more
aggressive breast surgery, with a significant increase in
the rate of contralateral prophylactic mastectomy
(CPM). This has been demonstrated in both single
institution studies (1,2), and in data from national
databases (3–5). These trends occur despite the lack of
evidence regarding the impact of CPM on survival,
particularly among patients without a known
increased risk for contralateral disease (6).
These trends have not occurred in a bubble. Over
this same time period we have seen the increasing sen-
sitivity of breast imaging, improvements in breast
reconstruction, and our understanding of family his-
tory, genetics and risk. This information is not only
available to clinicians, but is increasingly available to
our patients via mass media, the internet and through
social media. The institutional studies to date have
primarily focused on patients undergoing mastectomy
who then opted to also undergo CPM (1,2). However,
the threshold to undergo bilateral mastectomy (BM)
when a unilateral mastectomy (UM) is necessary, is
substantially different than opting for CPM when
breast conservation (BCT) is an option. This study
was performed to document trends in surgical thera-
pies for all women with operable breast cancer, and
identify those factors associated with both the decision
to forego BCT as well as the decision to undergo BM.
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METHODS
All biopsy-proven breast cancer patients seen at the
University of Michigan Comprehensive Cancer clinic
are presented at a multidisciplinary tumor board com-
posed of surgical, medical, radiation oncologists, radi-
ologists, pathologists and associated support staff.
Once the patient has undergone surgery, the data from
these discussions and the patient treatment records are
entered into our breast cancer database. With Institu-
tional Review Board approval, our prospective breast
cancer database was queried for all adult female
patients 21 years of age and older who underwent
surgery for a unilateral, primary stage I, II, or III
breast cancer at the University of Michigan Compre-
hensive Cancer Center between January 1, 2000 and
December 31, 2012. Women with bilateral cancers
and women with a prior history of breast cancer were
excluded from this study. The database was queried
to obtain information regarding age at diagnoses,
race/ethnicity, height and weight at diagnosis, and
smoking history. Details of surgical treatment, includ-
ing reconstruction, and tumor pathologic characteris-
tics (tumor size, nodal status, grade, estrogen and
progesterone receptor and HER2 status) were also col-
lected. BMI was calculated using the Quetelet Index.
For select time-periods, a detailed review of the
multidisciplinary visit was conducted to determine the
tumor board recommendations, whether the patient
opted for mastectomy, or the reason the patient was
recommended to undergo mastectomy by the surgeon.
For the purposes of this study, patient choice was
defined as a clinical situation where the surgeon
informed the patient that either BCT or mastectomy
was an option, as documented at the initial multidisci-
plinary tumor board visit, and the patient chose to
undergo mastectomy, either unilateral or bilateral.
Tumor size, as a reason for recommending mastec-
tomy, was defined as any situation where the size of
the tumor (including surrounding calcifications), com-
pared to the size of the breast was such that the sur-
geon felt the cosmesis would be poor, and thus
mastectomy was a better option. This also included
patients for whom neoadjuvant chemotherapy wasn’t
an option, or the tumor failed to decrease with neoad-
juvant chemotherapy. BCT failure included any
patient where BCT was attempted, but ultimately a
mastectomy was performed, even if patients had an
option for a re-excision lumpectomy. Multicentric dis-
ease was defined as more than one site of documented
disease that could not be incorporated into a single
lumpectomy. This did not include patients with suspi-
cious areas on imaging who opted not to undergo
biopsy, as they had opted for mastectomy. Additional
reasons for mastectomy included patients with diffuse
calcifications and those who could not undergo radia-
tion, either secondary to prior nonbreast cancer radia-
tion (as prior breast cancers were excluded),
pregnancy, or collagen-vascular disease. Specific
BRCA mutation status was not available in our data-
base for analysis as part of this study.
The distribution of categories was compared using
the chi-squared test statistic between lumpectomy and
mastectomy groups, and between unilateral and
bilateral groups within those having mastectomies.
P-values at or below 0.05 were considered significant.
RESULTS
After excluding patients with a prior history of
breast cancer or bilateral cancers, we identified 3,892
women with primary, unilateral breast cancer treated
between 2000 and 2012. During this time period,
2,325 (60%) underwent BCT, 1,092 (28%) had a UM
and 475 (12%) underwent a BM. Table 1 shows the
demographics and tumor characteristics and their
association with undergoing BCT, UM, and BM.
Younger age was a highly significant predictor of
undergoing not only mastectomy, but also opting for
CPM (p < 0.0001 for both). This was particularly true
among women under age 40, where only one-third of
women opted for BCT. The proportion rose to over
one-half of women age 40–49, and continued to rise
as women aged. Race was not a factor significantly
associated with BCT rates (p = 0.09). A similar per-
centage of white and African-American patients
underwent BCT. However, race was strongly associ-
ated with undergoing BM as opposed to UM, with
white women having CPM at a significantly higher
rate (33%) than African American (18%), Asian
(10%), or other races (22%) (p < 0.0001).
Overall, there was no difference in BCT rates or
CPM usage for patients with in situ disease versus
invasive disease. Among patients with invasive cancer,
there was a significantly lower rate of BCT in patients
with lobular carcinoma compared with ductal carci-
noma (48% versus 61%). Patients with “ductal with
lobular features” and other histologies had a similar
BCT rate to ductal carcinoma. Even though patients
with lobular carcinoma were more likely to undergo
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mastectomy, this was not a factor associated with
choosing to undergo BM, with a similar fraction to
other invasive histologies (p = 0.734).
Among patients with invasive disease, tumor size
was, as expected, associated with decreasing use of
BCT, but not removal of the contralateral breast. In
fact, increasing T-stage was associated with a
decreased likelihood of undergoing contralateral mas-
tectomy (p = 0.006). A similar pattern was seen with
nodal involvement. Patients with node positive disease
Table 1. Factors Associated with Surgical Decisions among Patients with First-Time, Primary, Unilat-
eral Breast Cancer
Breast conservation Unilateral mastectomy Bilateral mastectomy
% of mastectomiesN % of total N % of total N % of total
Age
<40 120 34 118 33 117 33 50
40–49 520 53 306 31 161 16 34
50–59 720 62 305 26 129 11 30
60–69 570 67 219 26 60 7 22
70–79 299 73 110 27 3 1 3
>80 95 71 34 25 5 4 13
p-value <0.0001 <0.0001
Race
White 1,970 60 867 27 429 13 33
African American 173 59 97 33 22 8 18
Asian 79 50 70 45 8 5 10
Other 103 58 58 33 16 9 22
p-value 0.0915 <0.0001
Invasive versus in situ
In situ 478 61 205 26 102 13 33




Ductal 1,401 61 617 27 264 12 30
Lobular 174 48 135 37 53 15 28
Ductal with lobular features 146 59 76 31 26 10 25
Other 112 61 49 27 23 13 32
p-value <0.0001 0.7430
T-stage
T1mic 42 62 25 37 1 1 4
T1a 174 64 67 24 33 12 33
T1b 421 74 90 16 55 10 38
T1c 716 67 246 23 107 10 30
T2 399 50 290 36 111 14 28
T3 24 16 95 64 30 20 24
p-value <0.0001 0.0058
Node positivity
No 1,380 68 442 22 208 10 32




<20 66 46 51 35 27 19 35
20–24.9 514 55 265 28 155 17 37
25–29.9 559 58 283 30 114 12 29
30–34.9 343 63 147 27 57 10 28
35–39.9 194 66 67 23 31 11 32
40–44.9 83 66 26 21 17 13 40




Yes 590 62 267 28 96 10 26
No 1,586 59 757 28 347 13 31
Unknown 127 60 59 28 25 12 30
p-value 0.2773 0.1990
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were less likely to have BCT (43% versus 68%,
p < 0.0001), but less likely to have contralateral mas-
tectomies (27% versus 32%, p = 0.05).
The year of treatment was strongly associated with
surgical decision making (Fig. 1). Over the period
from 2000 through 2012, we saw a decrease in the
BCT rate, ranging from a high of 68% in 2003 to a
low of 54% in 2012. During this time period, the UM
rate remained relatively constant while the BM
increased, from a low of 4% in 2000 to a high of
19% in 2011. The rise in bilateral mastectomies was
most significant among women less than age 40
(Fig. 2), however there were also rises among women
in their forties and fifties. These appear to have
increased at several years later, with the increase in
women <40 starting around 2002, but not increasing
for women 40–60 until around 2007 or 2008.
RECONSTRUCTION
As improved reconstruction options have been
implicated as a reason women increasingly opt to
undergo BM, we examined these trends. Over this


























Figure 1. Trends in breast conservation, uni-
lateral and bilateral mastectomy among






































Figure 2. Trends in patients with unilateral,
primary breast cancer undergoing bilateral
mastectomy by decade. While bilateral mas-
tectomy has risen among women <40 since
2002, it began increasing for women
between 40 and 60 around 2008.
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were offered consultation with plastic surgery to dis-
cuss reconstructive options. Among the 1,565 patients
undergoing unilateral or BM, 428 (27%) opted to
have immediate reconstruction and another 161
(10%) underwent delayed reconstruction. The most
common form of reconstruction was with implants,
with or without expanders (71%), while autologous
reconstruction represented 29%, with the most com-
mon technique being a pedicled transverse rectus
abdominis myocutaenous (TRAM) flap (17%).
Overall, from 2000 through 2012, although mas-
tectomy rates increased, we did not see an overall
change in the percentage of mastectomy patients who
opted for reconstruction, fluctuating between 24%
and 31% of patients undergoing either unilateral or
BM (p = NS). Over this time period, however, we did
see a shift from delayed reconstruction to immediate
reconstruction (Fig. 3). While throughout the years of
this study the ratio of allogeneic versus autologous
reconstruction remained constant, the type of autolo-
gous reconstruction changed, with pedicled TRAM
flaps dropping to a smaller percentage of autologous
reconstructions in favor of muscle sparing TRAMs
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Figure 4. Trends in patients undergoing
reconstruction after unilateral or bilateral
mastectomy.
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Breaking down mastectomy patients by unilateral
versus bilateral, there has also been no change over
time in the fraction of patients undergoing reconstruc-
tion over time for either group. Reconstruction was
consistently more common among women undergoing
BM than unilateral reconstruction (Fig. 4).
We also examined additional factors that may
impact a woman’s suitability to undergo reconstruc-
tion, and hence their decision to undergo mastectomy,
including tobacco use and BMI. These data are shown
in Table 1. Patients with a current or recent smoking
history (37% of patients), did not have a higher rate
of mastectomy compared with nonsmokers, and there
was no impact of smoking history on bilateral versus
unilateral mastectomies (p = 0.27 and 0.19 respec-
tively). Increasing BMI did impact surgical decision
making, with BCT increasing as BMI increased
(p < 0.0001). However, among women undergoing
mastectomy, there was no correlation between BMI
and the decision to undergo bilateral versus UM
(p = 0.13).
REASONS FOR MASTECTOMY
As the threshold for undergoing BM is lower when
a UM is recommended, we examined whether the rise
in CPM may be related to increased indications for
UM. To do this, we reviewed the charts for the 452
patients treated in 2002–2003, when the BCT rate
was at its highest (67%), and the 408 patients treated
in the year 2011 (when BCT was at 55%). Using
medical record data as described above, we differenti-
ated between those situations where the surgeon rec-
ommended mastectomy and those situations where the
patient was felt to be a candidate for BCT by the sur-
geon (and was offered both choices), and opted to
pursue mastectomy (unilateral or bilateral). Figure 5
shows the differences between these two time periods.
Over this time period, there were minimal differences
in the reasons women were recommended to undergo
mastectomy, with no statistically significant difference
between diffuse calcifications, tumor size, multicentric-
ity or inability to have radiation. In fact, there was a
small decrease in the percentage of patients recom-
mended to undergo mastectomy, specifically after a
failed attempt at BCT, secondary to our incorporation
of intraoperative margin analysis in 2009 (7).
In contrast, there was a dramatic and statistically
significant increase in the number of patients who
were eligible for BCT, but instead opted to undergo
mastectomy, rising from 19.6% in 2002–2003 to
31.3% in 2011 (p = 0.0169). The addition of a CPM
among these patients also rose, both for patients
requiring mastectomy (13–33%) and for patients opt-
ing for mastectomy, which was nearly half (45%) of
patients in 2002–2003, and rose to nearly 2/3rds
(63%) in 2011.
DISCUSSION
At the University of Michigan we have witnessed a

















Figure 5. Reasons for undergoing mastec-
tomy in 2002–2003 and 2011. Patient choice
includes all patients for whom breast conser-
vation was an option but the patient chose
unilateral or bilateral mastectomy.
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been described nationally. This is not, however, an
increasing use of CPM among patients recommended
to undergo mastectomy, but rather is associated with
a corresponding drop in BCT rates. This is despite a
strong institutional bias toward BCT. The use of bilat-
eral mastectomies rose from 4% to a high of 19%
and was strongly associated with young age, as only
one-third of patients under the age of 40 and one-half
of patients between 40 and 49 opted for BCT. The
trend is not explained by changes in the ages of our
patient population, as neither the median age nor the
proportion of patients under 40 has changed over this
time period.
Several articles have described the increased popu-
larity of the contralateral mastectomy, both at single
institutions and in national databases (1–5). When sim-
ply tracking whether a patient had a CPM or not, it
can sometimes be difficult to discern whether this rep-
resents women who are undergoing a UM and have
opted to remove the other breast (for reasons that
might not be related to risk reduction), or these are
women who were excellent candidates for BCT, and
opted for the more radical procedure primarily for pro-
phylaxis. Examining the CPM rate in the context of all
surgical decision making during this time period, and
excluding patients with bilateral cancer and prior
breast cancers (as this might influence decision mak-
ing), we note both a slight decrease in the number of
patients undergoing UM, and a decrease in the number
of patients undergoing BCT. Although this may reflect
a change in referral patterns, it suggests that this pat-
tern is not just women undergoing mastectomy opting
to have both breasts removed. Instead, a substantial
component of women undergoing BM today were
patients who 10 years ago would have undergone BCT
(8). This is confirmed by recent data from the National
Cancer Database which shows a small decrease in
lumpectomy rates between 2003 and 2010 (5).
Several factors have been associated with a higher
likelihood of undergoing a CPM. Our results suggest
there is a difference between those factors that may be
associated choosing BM among all patients, and those
factors associated with opting for a contralateral mas-
tectomy when committed to a UM. For example, race
has been strongly associated with surgical decision
making, with minorities less often getting CPM
(2,9,10). Our data show that overall, BCT rates were
extremely similar among the races, however, white
women, compared with other races, were more likely
to undergo BM compared with UM, a finding
consistent with other studies of CPM in different sam-
ples/settings (11,12). Histology showed the opposite
trend. There was no difference in BCT or BM rates
between in situ and invasive disease. Lobular histology
was associated with a significantly lower BCT rate
(potentially due to tumor size or failure to achieve
negative margins) Women with lobular histology
undergoing mastectomy were not more likely to
undergo BM, despite the perceived association with an
increased risk of contralateral disease, and in contrast
with studies showing increased CPM among women
with lobular histology (9,10). Increasing tumor size
expectedly correlates with mastectomy over BCT.
However, larger tumors are associated with a
decreased likelihood of BM. In a similar vein, nodal
positivity has a positive association with mastectomy,
but a negative association with BM. As any potential
benefit of prophylactic surgery decreases as the risk of
recurrence of the known cancer rises, these trends
may reflect appropriate counseling.
Age is by far the most significant factor for both, in
our study and others (1–3,9,10,13). Younger individu-
als may have more anxiety regarding recurrence and
second primary tumors in their lifetime, and are more
likely to harbor a genetic predisposition. Genetic test-
ing, and the increased identification of patients carry-
ing the BRCA1 and BRCA2 mutations, has certainly
contributed to this trend. In 2002, the turnaround
time for obtaining genetic testing results dropped sig-
nificantly, allowing for preoperative counseling and
shifting genetic testing from survivors to newly diag-
nosed patients. This may explain a jump in prophylac-
tic mastectomies prior to 2002, but over this time
period, and in the two specific time periods chosen for
comparison (2002–2003 and 2011), BRCA testing
was readily available. Though we were not able to
identify BRCA mutation status in our patients, we do
know that testing became easier for patients to obtain,
and the guidelines for genetic testing were broadened,
potentially identifying a slightly larger subset of
patients harboring a genetic predisposition. Thus we
may assume that more patients were tested and this
may have contributed to a fraction of CPM. However,
the analysis examining the reason for choosing mas-
tectomy was abstracted from the initial conversation
with the surgeon after multidisciplinary presentation,
at which point BRCA mutation status was rarely
known. Most patients informed the surgeon of their
decision to proceed with BM before referral to the
genetic counselor or testing.
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Breast imaging has changed considerably over this
time period with the introduction of digital mammog-
raphy and breast MRI. At the University of Michigan,
we do not recommend routine breast MRI for BCT
eligible patients, although an increasing number of
patients arrive with MRIs obtained by outside physi-
cians (radiologists, primary care physicians) prior to
their initial consultation. Despite this, when one
examines the reasons for patients undergoing mastec-
tomy, diffuse calcifications, tumor size and multicen-
tric disease (factors associated with sensitivity of
imaging), did not significantly change.
In addition to increasing rates of CPM, there have
been increasing rates of reconstruction and it has been
hypothesized that the availability of reconstruction
may be driving the mastectomy and BM rate (14,15).
Certainly, there may be some cases where mastectomy
and reconstruction can achieve a better cosmetic out-
come than BCT, and potentially avoid the complica-
tions of radiation. However, while reconstruction has
been statistically linked to CPM rates, this does not
necessarily translate to a causative relationship. At the
University of Michigan, we have offered consultation
with plastic surgery for any patient considering mas-
tectomy for all the years included in this study.
Although we have seen dramatic changes (more free
flaps, a shift to more immediate reconstruction), we
have not seen a rise in reconstruction rates among
women undergoing either unilateral or bilateral recon-
struction. In addition, factors that may impact the
ability to undergo reconstruction, such as obesity and
tobacco use, were not associated with the surgical
decision making. These data suggest that while recon-
struction rates may be increasing, changes in availabil-
ity or morbidity are not, in large measure, driving
BCT-eligible women toward either mastectomy or
BM. Rather, women opting for mastectomy and CPM
are doing so for other reasons, and then choosing
whether to have reconstruction.
This of course begs the question why women are
choosing more extensive surgery despite increased
recovery time, complications and no clear benefit to
survival (16). Although retrospective in nature, this
single institution study does benefit from a consistency
in practice over the time period being examined.
Despite a pro-BCT approach, consistent use of genetic
counseling/testing, consistent discussion of reconstruc-
tion options and referral to plastic surgery, avoidance
of breast MRI and no significant change in patient
age, BMI or presenting tumor stage, we too have seen
the same concerning increase in bilateral mastec-
tomies, particularly among younger women and even
when limited to BCT-eligible patients.
What has increased over this time period, for which
we have little control, is the public perception regard-
ing the risk of a second cancer, the importance of
family history, and the availability of prophylactic sur-
gery. Surveys of women opting for CPM have identi-
fied a substantial fear of recurrence and a desire to
prevent metastases and improve survival as quoted
reasons (11,12). However, many of these patients
overestimate their risk for either dying of disease or
developing a 2nd primary cancer, or misinterpret the
benefit of BM (11,17–19). The perceived benefit of
BM may be, to some degree, media driven. This has
often been referred to as the “Angelina Jolie effect,” a
fear that interest in genetic testing and bilateral mas-
tectomies would rise after the actress announced pub-
licly that she had undergone risk reduction surgery.
However, Angelina Jolie’s announcement was in May
of 2013, and the rise in bilateral mastectomies clearly
began at least a decade prior to this. More impor-
tantly, the news coverage regarding Angelina Jolie’s
breast cancer centered on her family history and her
BRCA status. In contrast, there have been many
media reports of celebrities with breast cancer under-
going BM and immediate reconstruction, without
explaining the decision making process or discussing
alternative options.
In addition to this media attention, there is likely
increased word of mouth as there are more breast can-
cer survivors and an increased willingness (if not
encouragement) to talk about it. And while the risk of
a contralateral cancer is low, estimated to be no more
than 4–5% over 10 years (20,21), given the preva-
lence of breast cancer, may be a large number of BCT
patients who reply, “if I had to do it all over again,
I’d have bilateral mastectomies,” when queried about
their decision; more when one includes patients dissat-
isfied with their cosmetic outcome.
While we clearly need better patient education
regarding risk and the true benefits and complications
of BM, the fact that higher education level seems to
correlate with opting for CPM suggests that education
alone may not be sufficient (22). It is clear that we
need additional studies addressing the reasons why
women choose BM, particularly those who are seem-
ingly excellent candidates for BCT. A more nuanced
approach to identifying and addressing patient fears
and other motivating factors may be needed to
614 • sabel et al.
counter the preconceived notions and mixed messages
originating from outside sources.
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